Valion Bio Inc Dossier
Qualitative Analysis
Business overview
Valion Bio Inc. (NASDAQ: VBIO), formerly known as Tivic Health Systems, Inc., is a late-stage clinical immunotherapeutics company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. The company completed a strategic transformation in April 2026, shifting its focus from consumer medical devices to a late-stage biopharmaceutical platform. Its lead drug candidate is Entolimod, a novel Toll-like receptor 5 (TLR5) agonist being developed as a medical countermeasure for Acute Radiation Syndrome (ARS) under the FDA's Animal Rule framework. Beyond biodefense, Valion Bio is expanding Entolimod's application into oncology supportive care, targeting chemotherapy-induced neutropenia and lymphocyte exhaustion. The company also owns Velocity Bioworks, a wholly owned contract development and manufacturing organization (CDMO) based in San Antonio, Texas, which provides domestic biomanufacturing capabilities for Entolimod and generates commercial revenue from third-party biotechnology clients.
Research as of 17 Jul 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expanding the clinical development of Entolimod into oncology supportive care, specifically targeting radiation-induced neutropenia, through a physician-sponsored clinical trial at Sheba Medical Center.
Expected impact: Provides independent clinical validation and opens up a second, potentially much larger commercial opportunity in the multi-billion-dollar supportive oncology market.
Leveraging the wholly owned subsidiary Velocity Bioworks to scale up domestic manufacturing of Entolimod and offer contract development and manufacturing services to third-party biotechnology companies.
Expected impact: Secures domestic supply chain control, reduces internal development costs, and establishes a secondary commercial revenue stream from third-party clients.
Advancing Entolasta, a second-generation, immunologically optimized TLR5 agonist designed for chronic applications and broader immunology indications.
Expected impact: Extends the company's intellectual property estate and broadens the therapeutic reach of the TLR5 platform into chronic immune dysfunction and oncology supportive care.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To secure domestic, vertically integrated manufacturing capabilities for Entolimod and establish a commercial CDMO business unit.
Financial impact: Increases operating expenses due to an expanded physical footprint, but positions the company for near-term commercial CDMO revenue and reduces long-term drug development costs.
Strategic Partnerships
High. Sheba Medical Center (ranked the #7 hospital in the world) will fund and conduct a clinical trial evaluating Entolimod in cancer patients receiving high-dose radiation [1.1.3].
Terms: Sheba Medical Center will fully fund and conduct the trial; Valion Bio will provide the investigational drug and support only limited study-related activities.
Medium. Secures exclusive commercial license rights to LarmorBio's BioScan-NMR platform, a next-generation nuclear magnetic resonance system.
Terms: Valion Bio secured the exclusive license and reference site arrangement at pre-institutional pricing ahead of LarmorBio's Series A financing.
High. Supports BLA-enabling in vivo testing of Entolimod as a medical countermeasure for Gastrointestinal Acute Radiation Syndrome (GI-ARS).
Terms: Valued at up to $7 million; NIAID will fully fund the required in vivo studies and support the FDA submission process.